Scientific and medical evidence informing expansion of hepatitis B treatment guidelines [0.03%]
科学和医学证据推动了乙肝治疗指南的扩展
Patrick T Kennedy,Lena Allweiss,Antonio Bertoletti et al.
Patrick T Kennedy et al.
Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) replication, normalise liver enzymes, and slow disease progression with excellent safety profiles. Treatment is not curati...
Rachel Halford,Jessica Hicks,Md Reazul Islam et al.
Rachel Halford et al.
Estimating the annual number of hepatitis C virus infections through vertical transmission at country, regional, and global levels: a data synthesis study [0.03%]
一项数据合成研究：估算各国家、区域和全球通过垂直传播的丙型肝炎病毒年度感染数
Adam Trickey,Adelina Artenie,Jordan J Feld et al.
Adam Trickey et al.
Background: The burden of hepatitis C virus (HCV) among women of childbearing age remains high globally. Studies have estimated that 7-12% of children born to women with HCV infection will acquire HCV, although around two...
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines [0.03%]
患者和公共健康视角助力扩大乙肝治疗指南的影响范围
Chari Cohen,Thomas Tu,Philippa C Matthews et al.
Chari Cohen et al.
Chronic hepatitis B is associated with considerable morbidity and mortality worldwide. People living with hepatitis B face physical, emotional, social, and professional impacts, reducing their quality of life. Treatment with nucleoside or n...
Gibril Ndow,Neil Gupta,Lindsey Hiebert-Suwondo et al.
Gibril Ndow et al.
Effect of gluten and wheat on symptoms and behaviours in adults with irritable bowel syndrome: a single-centre, randomised, double-blind, sham-controlled crossover trial [0.03%]
无麸质和无小麦饮食对肠易激综合征成人患者症状和行为的影响：单中心随机双盲对照交叉试验
Caroline Larissa Seiler,Gaston Horacio Rueda,Pedro Miguel Miranda et al.
Caroline Larissa Seiler et al.
Background: Many patients with irritable bowel syndrome (IBS) believe gluten or wheat triggers their symptoms. We compared symptomatic responses to wheat and gluten with gluten-free sham challenge in patients with IBS who...
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial [0.03%]
乌菜克比巴特（抗TL1A单克隆抗体）治疗中至重度溃疡性结肠炎的二期临床试验：TUSCANY-2研究是一项多中心、双盲、疗效持续评估直至病情缓解或出现预设终点的随机安慰剂对照试验
Silvio Danese,Jessica R Allegretti,Stefan Schreiber et al.
Silvio Danese et al.
Background: TNF-like ligand 1A (TL1A) is an emerging therapeutic target for inflammatory bowel disease. We evaluated the safety and efficacy of multiple doses of afimkibart, a TL1A-directed antibody, in patients with mode...
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial [0.03%]
荧光血管造影法用于直肠癌手术中预防吻合口瘘的院内靛氰绿试验（IntAct）：一项开放性随机对照试验
David Jayne,Julie Croft,Neil Corrigan et al.
David Jayne et al.
Background: Data are mixed on whether indocyanine green (ICG) fluorescence angiography can reduce the high rate of anastomotic leaks in patients undergoing surgery for rectal cancer. Therefore, we aimed to investigate the...